PAH News Briefs

Different Prostacyclin Analogs Can Help Treat Pediatric PAH

Researchers provided a comprehensive overview of the advantages and drawbacks of prostacyclin and its analogs for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients, as published in European Review for Medical and Pharmacological Sciences. “Epoprostenol can be effective against severe pulmonary hypertension,” the authors said. Iloprost, on the other hand, can treat severe…

hormone test

FSH Levels Predict Severity and Survival in Men With Idiopathic PAH

A Chinese research team has determined that levels of follicle-stimulating hormone (FSH) are higher in men with idiopathic pulmonary arterial hypertension (IPAH) and these levels strongly predict survival and disease severity. The study, published in the American Journal of Men’s Health, retrospectively reviewed the records of 116 men with IPAH who were hospitalized between 2016…

SIRT3 Enzyme Could Help Develop New PAH Therapies

The sirtuin 3 (SIRT3) enzyme may prevent the development of cardiovascular diseases such as pulmonary arterial hypertension (PAH) by protecting the mitochondria, according to a new review published in Free Radical Biology and Medicine. Therefore, sirtuin 3 agonists may serve as potential treatments for cardiovascular diseases, the authors said. SIRT3 is a deacetylase that regulates…

Breathing Reserve at Peak Exercise May Not Provide IPAH Prognostic Value

Researchers discovered that patients’ breathing reserve at peak exercise was not associated with disease outcomes in idiopathic pulmonary arterial hypertension (IPAH), as published in the International Journal of Cardiology Congenital Heart Disease. In contrast, they found an association between breathing reserve >30% at peak exercise and improved survival rates in patients with Eisenmenger syndrome (EIS).…

Targeting MMP-10 Could Be Therapeutic in PAH

The matrix metalloproteinase-10 (MMP-10) enzyme that’s produced by infiltrating macrophages contributes to vascular remodeling in pulmonary arterial hypertension (PAH), a new study published in the International Journal of Biological Sciences found. This finding suggests that circulating MMP-10 could be used as a potential therapy for PAH, Pei-Ling Chi and the coauthors of the study said.…

Inhibition of TRCP6 Shows Therapeutic Potential in PAH

Inhibition of transient receptor potential channel 6 (TRPC6) may be a novel therapeutic approach for treating pulmonary arterial hypertension (PAH), according to a new study published in the American Journal of Physiology – Lung Cellular and Molecular Physiology. The results showed that the administration of BI-749327, a selective blocker of TRCP6, resulted in roughly 50%…

Researchers Propose New Epigenetics-Based PAH Treatment Idea

Researchers identified a novel mechanism by which fibroblast growth factor 21 (FGF21) decreases hypoxia-induced pulmonary arterial hypertension (PAH), as published in the Journal of Cellular and Molecular Medicine. By inhibiting the negative regulatory effect of microRNA-130 (miR-130) on peroxisome proliferator-activated receptor gamma (PPARγ), this finding increases the understanding of the role of FGF21 in PAH…

depressed woman

Patients With PAH Report Higher Levels of Depression and Hopelessness

Korkmaz and colleagues sought to investigate the frequency of suicidal ideation and its association with other clinical characteristics in patients with pulmonary arterial hypertension (PAH) and discovered that PAH patients reported higher levels of hopelessness and depression than healthy individuals, according to a study published in The Primary Care Companion For CNS Disorders. The research…

3D Engineered Heart Model Created From PAH Patient Cells

Researchers have created an initial 3-dimensional (3D) heart model from pulmonary arterial hypertension (PAH) patient cells to better study the disease. The study, published in Cells, used induced pluripotent stem cells (iPSCs) from a PAH patient to create a right heart dysfunction (RHD) model to further investigate the mechanisms of right ventricular overload. During the…

Adding Echocardiography to Scoring System Refines Risk Assessment in PAH

Risk prediction in pulmonary arterial hypertension (PAH) was more accurate when combining the updated, abridged version of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL Lite 2.0) with echocardiographic parameters, a new study found. Read more about PAH diagnosis According to the authors of the study, “These findings clearly show the advantage…

Next post in PAH News Briefs